DLA Piper is a global law firm with a significant presence in the Canadian life sciences space. The firm advises a number of industry clients with matters including corporate financing, transactions, IP, and product liability litigation.
IP and technology group chair Sangeetha Punniyamoorthy is frequently active for pharmaceutical clients in the patent litigation as well as in IP counseling and strategy. Punniyamoorthy is currently active for Vertex Pharmaceuticals in connection with brand protection and strategy.
David Neave and Rebecca von Rüti are standouts in the firm’s product liability and class actions practice, supporting the firm’s national recommended ranking in the area. Both are currently active for a number of high-profile pharmaceutical clients, including Bristol-Myers Squibbs in a proposed class action in British Columbia related to opioid products. Neave was shortlisted for the Canadian Product Liability Attorney of the Year award for his work in the area.
In the financial and corporate space, Noam Goodman is one of the firm’s well-versed practitioners for life sciences deals. His practice focuses on assisting life sciences companies in corporate financing, transactions, licensing agreements, and other areas. Goodman recently advised Bloom Burton Development Corp on its investment into Triumvira Immunologics. He was shortlisted for the Canadian Financial & Corporate Attorney of the Year in 2020.